Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

FHD-286

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Foghorn Therap

Drug class:

SMARCA2 inhibitor, SMARCA4 inhibitor

Related drugs:

MLL rearrangement + FLT3 mutation	Acute Myelogenous Leukemia	MLL rearrangement + FLT3 mutation	Acute Myelogenous Leukemia	FHD-286 Sensitive: D – Preclinical FHD-286 Sensitive : D	FHD-286 Sensitive: D – Preclinical FHD-286 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	revumenib + FHD-286 Sensitive: D – Preclinical revumenib + FHD-286 Sensitive : D	revumenib + FHD-286 Sensitive: D – Preclinical revumenib + FHD-286 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D